111
Views
5
CrossRef citations to date
0
Altmetric
Haematological Malignancy

Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias

, , , , , , , & show all
Pages 33-37 | Published online: 04 Sep 2013

References

  • Nature biotechnology, Vol 18 supplements 2000. http://biotech.nature.com.
  • Frost BM, Nygreen P, Gustafson G, Forrestier E, Jonsson OG, Kanerva J, Nygaard R, Schmiegelow K, Larsson R, Lonnerholm G. Increased in vitro cellular drug resistance is related to poor outcome in high-risk childhood acute lympoblastic leukaemia. Br J Haematol 2003;122:376–385.
  • Tallman MS, Robert S, Mocharmuk MD. Acute myeloid leukaemia: Review of current treatment strategies 2003. www.medscape.com.
  • Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993;81:2215–2222.
  • Hart SM, Ganeshaguru K, Mehta A. Multidrug resistance in haematological malignancies. CME Bull Haematol 2000;3:1–8.
  • Leith CP, Kopecky KJ, Godwin J, McConnel T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukaemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biological subgroup with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study Blood 1997;89: 3323–3329.
  • Denhoer ML, Kapaun P, Pieters R, Kazemier KM, Janka-Schaub GE, Veerman AJP. Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: Relationship with in vitro drug resistance. Br J Haematol 1999;105: 876–882.
  • Ravindranath Y, Arceci RJ. Drug resistance in acute leukemia Dim: Pui, CH, (pnyt) Treatment of acute leukemias: New direction for clinical research. Totowa NJ: Humana Press; 2003.
  • Sonneveld P. Multidrug resistance in haematological malig-nancies. J Int Med 2000;247:521–534.
  • Kaspers GJ, Veerman AJ, Pieters R, Van Zantwijk CH, Smets LA, Van ering ER, Van Der Does-Van Der Berg A. In Vitro cellular drug resistance and prognosis in newly diagnosed childhood lymphoblastic leukaemia. Blood 1997;90: 2723–2729.
  • Klumper E, Ossenkoppele G, Pieters R, Huismans DR, Loonen AH, Rottier A, Westra G, Veerman AJ. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 1996;93:903–910.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.